Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AKTX 
Akari Therapeutics PLC (AKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.53
1 Year Target Price $4.53
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.22% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.96M USD | Price to earnings Ratio - | 1Y Target Price 4.53 |
Price to earnings Ratio - | 1Y Target Price 4.53 | ||
Volume (30-day avg) 1 | Beta 0.26 | 52 Weeks Range 0.29 - 1.73 | Updated Date 12/6/2025 |
52 Weeks Range 0.29 - 1.73 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.11 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.56% | Return on Equity (TTM) -112.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11748768 | Price to Sales(TTM) - |
Enterprise Value 11748768 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 | Shares Outstanding 32614731 | Shares Floating 15835104195 |
Shares Outstanding 32614731 | Shares Floating 15835104195 | ||
Percent Insiders 31.48 | Percent Institutions 3.75 |
Upturn AI SWOT
Akari Therapeutics PLC
Company Overview
History and Background
Akari Therapeutics PLC is a late-stage biopharmaceutical company focused on developing therapies for rare inflammatory diseases. It was formed through the reverse merger of Monovitro AB and Cambridge Nanotherm Ltd. in 2014, with a subsequent name change. The company has been actively advancing its lead candidate, nomacopan, through clinical trials.
Core Business Areas
- Complement Inhibition Platform: Akari's primary focus is on developing therapies that inhibit the complement system, a crucial part of the immune system. Their lead drug candidate, nomacopan, targets this system to treat various rare diseases.
Leadership and Structure
Akari Therapeutics PLC is led by a management team with experience in drug development and the biopharmaceutical industry. The company operates with a lean structure, typical of clinical-stage biotechs, with a focus on research and development, clinical operations, and regulatory affairs. Key leadership roles include CEO, CSO, and CFO.
Top Products and Market Share
Key Offerings
- Product Name 1: Nomacopan (AK002): A late-stage, first-in-class, self-assembling tetravalent small peptide that inhibits the complement system. It is being developed for the treatment of various rare inflammatory diseases, including bullous pemphigoid (BP) and cold agglutinin disease (CAD). Competitors in the broader complement inhibition space include companies developing antibodies and other small molecules targeting different complement pathways. Specific market share data for nomacopan is not yet available as it is still in clinical development.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the rare disease and autoimmune disorder segments, is characterized by significant unmet medical needs, high R&D costs, lengthy development timelines, and a strong regulatory environment. There is a growing demand for novel therapies that can offer improved efficacy and safety profiles.
Positioning
Akari Therapeutics PLC is positioned as a developer of novel complement inhibitors for rare diseases. Its competitive advantage lies in the potential of nomacopan to address multiple rare inflammatory conditions with a single molecule, leveraging a differentiated mechanism of action.
Total Addressable Market (TAM)
The TAM for rare inflammatory diseases is substantial and growing. For bullous pemphigoid and cold agglutinin disease alone, the combined market represents billions of dollars. Akari Therapeutics PLC is positioned to capture a significant portion of this market if nomacopan successfully navigates clinical trials and receives regulatory approval. However, its current market penetration is zero as it is pre-commercial.
Upturn SWOT Analysis
Strengths
- Proprietary complement inhibition platform with nomacopan.
- Focus on rare diseases with significant unmet medical needs.
- Late-stage clinical development for lead candidate.
- Experienced management team.
- Potential for broad applicability of nomacopan across multiple indications.
Weaknesses
- Limited product pipeline beyond nomacopan.
- Reliance on external funding for continued development.
- Clinical trial risks and regulatory hurdles.
- Lack of established commercial infrastructure.
- High cost of drug development.
Opportunities
- Successful clinical trial outcomes and regulatory approvals.
- Partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new rare disease indications.
- Growing market demand for effective treatments for inflammatory diseases.
- Advancements in complement biology research.
Threats
- Failure to meet clinical endpoints or achieve regulatory approval.
- Emergence of competing therapies with superior efficacy or safety.
- Intense competition in the rare disease space.
- Changes in healthcare policy and reimbursement.
- Economic downturns impacting investment in biopharmaceuticals.
Competitors and Market Share
Key Competitors
- Horizon Therapeutics plc (HZNP) (Acquired by Amgen)
- Alexion Pharmaceuticals, Inc. (ALXN) (Acquired by AstraZeneca)
- Sobi (Swedish Orphan Biovitrum AB)
- ChemoCentryx, Inc. (CCXY) (Acquired by Amgen)
- Regeneron Pharmaceuticals, Inc. (REGN)
Competitive Landscape
Akari Therapeutics PLC operates in a highly competitive landscape for rare diseases and autoimmune conditions. Its advantage lies in its novel complement inhibition mechanism, which could offer a differentiated treatment option. However, established players have significant resources, commercial infrastructure, and existing product portfolios. Akari's success depends on demonstrating clear clinical superiority and navigating complex regulatory pathways against well-funded competitors.
Growth Trajectory and Initiatives
Historical Growth: Akari Therapeutics PLC's growth has been characterized by advancements in its clinical pipeline, particularly the progression of nomacopan through various phases of clinical trials. This involves increased investment in R&D and operational scaling.
Future Projections: Future growth is heavily contingent on the successful clinical development and regulatory approval of nomacopan. Analyst projections would focus on potential peak sales upon commercialization and the value of its pipeline in addressing unmet medical needs. (Note: Specific analyst projections require access to current market research.)
Recent Initiatives: Recent initiatives likely include the advancement of nomacopan through its ongoing clinical trials (e.g., Phase 3 trials for BP and CAD), seeking regulatory feedback, and potentially exploring new indications or strategic partnerships.
Summary
Akari Therapeutics PLC is a clinical-stage biopharmaceutical company with a promising complement inhibitor, nomacopan, targeting rare inflammatory diseases. Its strengths lie in its novel platform and focus on unmet medical needs. However, the company faces significant risks associated with clinical trial outcomes, regulatory approvals, and intense competition. Strong execution in clinical development and successful navigation of the regulatory landscape are critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations (SEC Filings, Press Releases)
- Biopharmaceutical Industry Research Reports
- Financial News Outlets
- ClinicalTrials.gov
- Market Research Databases
Disclaimers:
This analysis is based on publicly available information as of the last update. It is for informational purposes only and does not constitute financial or investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data and competitor analysis are estimations and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akari Therapeutics PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-09-21 | CEO, President & Director Mr. Abizer Gaslightwala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.akaritx.com |
Full time employees 8 | Website https://www.akaritx.com | ||
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.